What is Mersana Therapeutics Profitability Rank?
Mersana Therapeutics has the Profitability Rank of 1. It has had trouble to make a profit.
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way. It is based on these factors:
1.
Operating Margin %
2.
Piotroski F-Score
3. Trend of the
Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.
4. Consistency of the profitability
5. Predictability Rank
Mersana Therapeutics's Operating Margin % for the quarter that ended in Dec. 2023 was -195.57%. As of today, Mersana Therapeutics's Piotroski F-Score is 3.
Competitive Comparison of Mersana Therapeutics's Profitability Rank
For the Biotechnology subindustry, Mersana Therapeutics's Profitability Rank, along with its competitors' market caps and Profitability Rank data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mersana Therapeutics's Profitability Rank Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Mersana Therapeutics's Profitability Rank distribution charts can be found below:
* The bar in red indicates where Mersana Therapeutics's Profitability Rank falls into.
Mersana Therapeutics Profitability Rank Calculation
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.
Mersana Therapeutics has the Profitability Rank of 1. It has had trouble to make a profit.
Profitability Rank is not directly related to the Financial Strength. But if a company is consistently profitable, its financial strength will be stronger.
Profitability Rank is based on these factors:
1. Operating Margin %
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
Mersana Therapeutics's Operating Margin % for the quarter that ended in Dec. 2023 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
2. Piotroski F-Score
Warning Sign:
Piotroski F-Score of 3 is low, which usually implies poor business operation.
The zones of discrimination were as such:
Good or high score = 8 or 9
Bad or low score = 0 or 1
Mersana Therapeutics has an F-score of 3. It is a bad or low score, which usually implies poor business operation.
3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.
Warning Sign:
Mersana Therapeutics Inc operating margin has been in a 5-year decline. The average rate of decline per year is -30.3%.
4. Consistency of the profitability
5. Predictability Rank
Mersana Therapeutics (Mersana Therapeutics) Business Description
Traded in Other Exchanges
Address
840 Memorial Drive, Cambridge, MA, USA, 02139
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefits to patients. The Company's early stage programs include XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING agonist ADC developed using the Company's Immunosynthen platform and targeting a novel epitope of human epidermal growth factor receptor 2. The Company also has two earlier stage preclinical candidates, XMT-2068 and XMT-2175, both of which leverage the Company's Immunosynthen platform and target tumor-associated antigens.
Executives
| Anna Protopapas |
director, officer: President and CEO |
MILLENNIUM PHARMACEUTICALS, INC., 40 LANDSDOWNE STREET, CAMBRIDGE MA 02139 |
| Mohan Bala |
officer: SVP, Chief Development Officer |
C/O MERSANA THERAPEUTICS, INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139 |
| Tushar Misra |
officer: Chief Manufacturing Officer |
840 MEMORIAL DRIVE, CAMBRIDGE MA 02139 |
| Brian Deschuytner |
officer: Sr. VP, Finance & Product stgy |
840 MEMORIAL DRIVE, CAMBRIDGE MA 01776 |
| Ashish Mandelia |
officer: VP, Controller |
840 MEMORIAL DRIVE, CAMBRIDGE MA 02139 |
| Timothy B Lowinger |
officer: Chief Scientific Officer |
840 MEMORIAL DRIVE, CAMBRIDGE MA 02139 |
| Alejandra Carvajal |
officer: Chief Legal Officer |
C/O CERULEAN PHARMA INC., 840 MEMORIAL DRIVE, 5TH FLOOR, CAMBRIDGE MA 02139 |
| Ecor1 Capital, Llc |
10 percent owner |
357 TEHAMA STREET #3, SAN FRANCISCO CA 94103 |
| Arvin Yang |
officer: Chief Medical Officer |
840 MEMORIAL DRIVE, CAMBRIDGE MA 02139 |
| Hack Andrew A. F. |
director |
300 THIRD STREET, FIRST FLOOR, CAMBRIDGE MA 02142 |
| Michael J. Kaufman |
officer: Sr VP Chmistry, Man & Control |
840 MEMORIAL DRIVE, CAMBRIDGE MA 02139 |
| Allene M. Diaz |
director |
C/O ALLENA PHARMACEUTIALS, INC., ONEW NEWTON EXECUTIVE PARK SUITE 202, NEWTON MA 02462 |
| Eva M. Jack |
officer: CBO, Treasurer & Secretary |
840 MEMORIAL DRIVE, CAMBRIDGE MA 02139 |
| Lawrence M Alleva |
director |
1000 WINTER STREET, SUITE 3300, WALTHAM MA 02451 |
| Scott D Sandell |
10 percent owner |
|
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
MRSN has been successfully added to your